Title
Author
Derksen RH
Address
Department of Rheumatology and Clinical Immunology, University
Hospital, Utrecht, The Netherlands.
Source
Semin Arthritis Rheum, 1998 Jun, 27:6, 335-47
Abstract
OBJECTIVE: This study was performed to evaluate in vivo and in vitro
data on the effects of the adrenal steroid dehydroepiandrosterone
(DHEA) with emphasis on its potential use in the treatment of systemic
lupus erythematosus (SLE). METHODS: The literature dealing with DHEA
was reviewed. RESULTS: Initially, research on DHEA focused on effects
of DHEA in relation to obesity. Over the past decade, research
stimulated by associations between the physiological decline in DHEA
and aging, cardiovascular disease, changes in metabolism, brain
function, and immune senescence have generated insight into the many
effects that DHEA or its metabolites may have. In SLE a role for sex
hormones in both the etiopathogenesis and disease activity is
recognized. In SLE, as in aging, low DHEA levels are frequently found,
especially with corticosteroid treatment. CONCLUSIONS: Research data in
the elderly, on both hormonal and immunologic effects, suggest that
DHEA may become an adjunctive treatment for SLE patients.
Language of Publication
English
Unique Identifier
98327254
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*DT/PP; Prasterone|PH/*TU
MeSH Heading
Aged; Aged, 80 and over; Animal; Clinical Trials; Drug Administration
Routes; Human; In Vitro; Sex Hormone-Binding Globulin|DE; Sex
Hormones|BL
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0049-0172
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Sex Hormone-Binding Globulin); 0 (Sex Hormones); 53-43-0
(Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Suzuki N; Suzuki T; Sakane T
Address
Institute of Medical Science, St. Marianna University School of
Medicine, Kanagawa, Japan.
Source
Ann Med Interne (Paris), 1996, 147:4, 248-52
Abstract
There is strong evidence to implicate the involvement of sex steroid
hormones in the pathogenesis of systemic lupus erythematosus (SLE).
However, the precise role of an imbalance of circulating sex hormones
in the pathogenesis of the disease remains to be fully elucidated.
Recent studies of our own as well as others have shown that
dehydroepiandrosterone (DHEA), an intermediate compound in testosterone
synthesis, significantly up-regulates IL-2 production of normal T cells
and that administration of exogenous DHEA or IL-2 via a vaccinia
construct to mice with murine lupus dramatically reverses their
clinical autoimmune diseases. Thus, it is possible that in patients
with SLE, the reported deficiency of IL-2 production is associated with
defective DHEA activity. Indeed, we found that nearly all of the
patients examined have very low levels of serum DHEA. The decreased
DHEA levels are not simply a reflection of long term corticosteroid
treatment, since serum samples drawn at the onset of disease, prior to
any corticosteroid treatment also contained low levels of DHEA. In
addition, supplementation with DHEA of the in vitro cultures of T cells
restored impaired IL-2 production in patients with SLE. Thus, it would
be suggested that defects of IL-2 synthesis in patients with SLE are at
least in part due to the low DHEA activity in the serum, and that
supplementation of DHEA could improve clinical manifestations in
patients with SLE.
Language of Publication
English
Unique Identifier
97110592
----------------------------------------------------------------------------
MeSH Heading (Major)
Interleukin-2|*PD; Lupus Erythematosus, Systemic|GE/*PP;
Prasterone|ME/PD/*PH; T-Lymphocytes|*PH
MeSH Heading
Animal; Human; Mice
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0003-410X
Country of Publication
FRANCE
----------------------------------------------------------------------------
---------------------------------------------------------------------------
Title
Author
van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
Address
Division of Immunology and Rheumatology, Stanford University Medical
Center, CA 94305-5111, USA.
Source
J Rheumatol, 1998 Feb, 25:2, 285-9
Abstract
OBJECTIVE: To determine whether longterm therapy (up to 1 year) with
the weakly androgenic adrenal steroid dehydroepiandrosterone (DHEA) is
feasible and beneficial in patients with mild to moderate systemic
lupus erythematosus (SLE). METHODS: In a prospective, open label,
uncontrolled longitudinal study 50 female patients (37 premenopausal,
13 postmenopausal) with mild to moderate SLE were treated with oral
DHEA 50-200 mg/day. RESULTS: DHEA therapy was associated with increases
in the serum levels of DHEA, DHEA sulfate, and testosterone and, for
those patients who continued DHEA, with decreasing disease activity
measured by SLE Disease Activity Index score (p < 0.01), patient global
assessment (p < 0.01), and physician global assessment (p < 0.05),
compared to baseline. Concurrent prednisone doses were reduced (p <
0.05). These improvements were sustained over the entire treatment
period. Thirty-four patients (68%) completed 6 months of treatment and
21 patients (42%) completed 12 months. Mild acneiform dermatitis was
the most common adverse event (54%). Pre and postmenopausal women
experienced similar efficacy and adverse effects from DHEA. CONCLUSION:
DHEA was well tolerated and appeared clinically beneficial, with the
benefits sustained for at least one year in those patients who
maintained therapy.
Language of Publication
English
Unique Identifier
98149464
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*DT; Prasterone|*AD/AE/BL
MeSH Heading
Adult; Dehydroepiandrosterone Sulfate|BL; Feasibility Studies; Female;
Human; Longitudinal Studies; Middle Age; Postmenopause; Prednisone|AD;
Premenopause; Prospective Studies; Support, Non-U.S. Gov't;
Testosterone|BL; Time Factors; Treatment Outcome
----------------------------------------------------------------------------
Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE
ISSN
0315-162X
Country of Publication
CANADA
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Van Vollenhoven RF; McGuire JL
Address
Division of Immunology and Rheumatology, Stanford University Medical
Center, California, USA.
Source
Ann Med Interne (Paris), 1996, 147:4, 290-6
Abstract
Several lines of investigation led to the consideration of
dehydroepiandrosterone (DHEA) as a candidate for hormonal therapy in
systemic lupus erythematosus, including DHEA deficiency in patients
with SLE, the effects of sex steroids on SLE, the immunomodulatory
effects of DHEA, and the results of DHEA in animal models of SLE.
Uncontrolled observations in 50 patients suggested that DHEA has
overall benefits for lupus activity, alleviating specific lupus
symptoms as well the systemic manifestations of lupus, with incremental
benefits over 3 to 12 months of treatment. DHEA, which was very well
tolerated and safe, appeared to decrease the number of lupus flares and
to have a steroid sparing effect. These results were confirmed in a
small placebo-controlled trial, although the results were of borderline
statistical significance. Currently, a number of additional trials with
DHEA are underway, and it is anticipated that DHEA will find its place
as a useful agent in the treatment of SLE.
Language of Publication
English
Unique Identifier
97110599
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*DT; Prasterone|*TU
MeSH Heading
Human
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0003-410X
Country of Publication
FRANCE
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Robinson T; Neuwelt CM
Address
Livermore Veterans Affairs, Medical Center, California 94550, USA.
Source
Ann Med Interne (Paris), 1996, 147:4, 276-80
Abstract
Neuropsychiatric lupus can present with a broad spectrum of severity,
ranging from mild chronic symptomatology to acute life threatening
illness. There are no accepted diagnostic or classification criteria,
but most agree that the manifestations can be described as representing
diffuse CNS insult or a more focal or localized process. The
pathogenesis is unknown, but it is likely that there is more than one
mechanism given the heterogeneous clinical presentations. It is
probable that autoantibody formation, vascular injury, and cytokine
production all play a role. There are no randomized controlled trials
to help guide therapeutic decision making, but there is data to suggest
that treatment of severe NPSLE with IV cyclophosphamide may be of
benefit. Additionally, there may be a role for IVGG or synchronized
plasmapheresis in cases that fail to respond to IV-CYC. An important
role for sex steroids in the etiology of NPSLE is suggested by various
observations. Investigational therapy with dehydroepiandrosterone
(DHEA) appeared to have benefits with respect to milder symptoms of
NPSLE.
Language of Publication
English
Unique Identifier
97110597
----------------------------------------------------------------------------
MeSH Heading (Major)
Central Nervous System Diseases|DI/*ET/TH; Lupus Erythematosus,
Systemic|DI/*ET/TH; Mental Disorders|DI/*ET/TH; Sex Hormones|*PH
MeSH Heading
Combined Modality Therapy; Human
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0003-410X
Country of Publication
FRANCE
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Lahita RG
Address
Division of Rheumatology and Connective Tissue Diseases, Roosevelt/St.
Lukes Medical Center, New York, New York, USA.
Source
Int J Fertil Menopausal Stud, 1996 Mar, 41:2, 156-65
Abstract
The autoimmune diseases are more common in women than men. The actual
prevalence ranges from the high of 10 to 15 females for each male for
systemic lupus erythematosus to four females for every male with
rheumatoid arthritis. Though these diseases are found in the very young
and the aged, the high prevalence is observed after puberty in most
patients. These diseases vary with regard to severity, and most
investigators suspect that the signs and symptoms of these diseases
vary with menstrual cycle and change severity during pregnancy. The
collagen diseases are devastating to the health of young women.
Rheumatoid arthritis occurring at a mean age of 40 years results in
debilitating erosive changes in bone with morning stiffness and
eventual crippling. Systemic lupus erythematosus, Sjögren's syndrome
and others, common to women of the childbearing years, act in several
ways to destroy organ systems of the body. Virtually any organ system
of the female anatomy can be affected by these illnesses. In the case
of lupus, the disease has protean manifestations, such as
procoagulation, renal destruction, skin disease, unrelenting
arthropathy and arthritis, and encephalopathy (to name only a few). The
underlying mechanisms are not known; however, the immune system acts to
destroy tissue via immune complex deposition and through the action of
cytotoxic lymphocyte activity. There is an association of both clinical
signs and autoantibody subpopulations with markers of the HLA-D or MHC
II locus on chromosome 6. No constitutive gene for any of the collagen
vascular diseases has been identified in the human. Evidence exists to
support an altered metabolism of estrogens and androgens in patients
with these diseases. Recent data also indicate that increased estrogen
levels might initiate autoimmune diseases in many women and men.
Estrogen hydroxylation is increased in both men and women with
autoimmune diseases like lupus. The mechanisms are unknown, although
estrogenic metabolites have been shown to increase B cell
differentiation and activate T cells. Moreover, isolated cases of
hyperprolactinemia have been observed in association with these
hyperestrogenic states, and treatment of hyperprolactinemia has been
shown to ameliorate diseases like lupus. Androgen oxidation is also
increased in patients with autoimmune disease, but this abnormality has
been observed only in patients with lupus, and only women at that. The
result is that women with autoimmune diseases like lupus and rheumatoid
arthritis have lower plasma androgens than control cases. These data
have supported the use of weak androgens, e.g., DHEA, for the treatment
of lupus.
Language of Publication
English
Unique Identifier
96268528
----------------------------------------------------------------------------
MeSH Heading (Major)
Connective Tissue Diseases|*/ET/PP/TH; Sex Hormones|*PH
MeSH Heading
Animal; Arthritis, Rheumatoid|ET/PP/TH; Collagen Diseases|ET/PP/TH;
Female; Human; Lupus Erythematosus, Systemic|ET/PP/TH; Male; Pregnancy;
Risk Factors; Sex Factors; Sjogren's Syndrome|ET/PP/TH
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
1069-3130
Country of Publication
UNITED STATES
----------------------------------------------------------------------------
Title
systemic lupus erythematosus.
Author
Suzuki N; Suzuki T; Sakane T
Address
Institute of Medical Science, St. Marianna University School of
Medicine, Kanagawa, Japan.
Source
Ann Med Interne (Paris), 1996, 147:4, 248-52
Abstract
There is strong evidence to implicate the involvement of sex steroid
hormones in the pathogenesis of systemic lupus erythematosus (SLE).
However, the precise role of an imbalance of circulating sex hormones
in the pathogenesis of the disease remains to be fully elucidated.
Recent studies of our own as well as others have shown that
dehydroepiandrosterone (DHEA), an intermediate compound in testosterone
synthesis, significantly up-regulates IL-2 production of normal T cells
and that administration of exogenous DHEA or IL-2 via a vaccinia
construct to mice with murine lupus dramatically reverses their
clinical autoimmune diseases. Thus, it is possible that in patients
with SLE, the reported deficiency of IL-2 production is associated with
defective DHEA activity. Indeed, we found that nearly all of the
patients examined have very low levels of serum DHEA. The decreased
DHEA levels are not simply a reflection of long term corticosteroid
treatment, since serum samples drawn at the onset of disease, prior to
any corticosteroid treatment also contained low levels of DHEA. In
addition, supplementation with DHEA of the in vitro cultures of T cells
restored impaired IL-2 production in patients with SLE. Thus, it would
be suggested that defects of IL-2 synthesis in patients with SLE are at
least in part due to the low DHEA activity in the serum, and that
supplementation of DHEA could improve clinical manifestations in
patients with SLE.
Language of Publication
English
Unique Identifier
97110592
----------------------------------------------------------------------------
MeSH Heading (Major)
Interleukin-2|*PD; Lupus Erythematosus, Systemic|GE/*PP;
Prasterone|ME/PD/*PH; T-Lymphocytes|*PH
MeSH Heading
Animal; Human; Mice
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0003-410X
Country of Publication
FRANCE
CAS Registry/EC Number
0 (Interleukin-2); 53-43-0 (Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
van Vollenhoven RF; Engleman EG; McGuire JL
Address
Division of Immunology and Rheumatology, Stanford University Medical
Center, CA 94305.
Source
Arthritis Rheum, 1994 Sep, 37:9, 1305-10
Abstract
OBJECTIVE. To determine if dehydroepiandrosterone (DHEA) has clinical
benefits in patients with systemic lupus erythematosus (SLE). METHODS.
Ten female patients with mild to moderate SLE and various disease
manifestations were given DHEA (200 mg/day orally) for 3-6 months. The
patients were given other medications as clinically indicated, and
followed with respect to overall disease activity and specific outcome
parameters. RESULTS. After 3-6 months of DHEA treatment, indices for
overall SLE activity including the SLEDAI (SLE Disease Activity Index)
score and physician's overall assessment were improved, and
corticosteroid requirements were decreased. Of 3 patients with
significant proteinuria, 2 showed marked and 1 modest reductions in
protein excretion. DHEA was well tolerated, the only frequently noted
side effect being mild acneiform dermatitis. CONCLUSION. DHEA shows
promise as a new therapeutic agent for the treatment of mild to
moderate SLE. Further studies of DHEA in the treatment of SLE are
warranted.
Language of Publication
English
Unique Identifier
95032242
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|BL/*DT/PP; Prasterone|AE/*TU
MeSH Heading
Adrenal Cortex Hormones|AD/TU; Adult; Aged; Androgens|BL; Female;
Human; Middle Age; Proteinuria|DT; Support, Non-U.S. Gov't
----------------------------------------------------------------------------
Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE
ISSN
0004-3591
Country of Publication
UNITED STATES
CAS Registry/EC Number
0 (Adrenal Cortex Hormones); 0 (Androgens); 53-43-0 (Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
van Vollenhoven RF; Engleman EG; McGuire JL
Address
Division of Immunology and Rheumatology, Stanford University Medical
Center, CA 94305, USA.
Source
Arthritis Rheum, 1995 Dec, 38:12, 1826-31
Abstract
OBJECTIVE: To determine if dehydroepiandrosterone (DHEA) is beneficial
in the treatment of systemic lupus erythematosus (SLE). METHODS: In a
double-blind, placebo-controlled, randomized trial, 28 female patients
with mild to moderate SLE were given DHEA 200 mg/day or placebo for 3
months. Outcomes included the SLE Disease Activity Index (SLEDAI)
score, patient's and physician's overall assessments of disease
activity, and concurrent corticosteroid dosages (which were adjusted as
clinically indicated). RESULTS: In the patients who were receiving
DHEA, the SLEDAI score, patient's and physician's overall assessment of
disease activity, and concurrent prednisone dosage decreased, while in
the patients taking placebo, small increases were seen. The difference
in patient's assessment between the groups was statistically
significant (P = 0.022, adjusted). Lupus flares occurred more
frequently in the placebo group (P = 0.053). Mild acne was a frequent
side effect of DHEA. CONCLUSION: DHEA may be useful as a therapeutic
agent for the treatment of mild to moderate SLE. Further studies of
DHEA in the treatment of SLE are warranted.
Language of Publication
English
Unique Identifier
96110687
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*DT; Prasterone|*TU
MeSH Heading
Adult; Chi-Square Distribution; Double-Blind Method; Drug Therapy,
Combination; Female; Human; Prednisone|AD; Severity of Illness Index;
Support, Non-U.S. Gov't
----------------------------------------------------------------------------
Publication Type
CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
ISSN
0004-3591
Country of Publication
UNITED STATES
CAS Registry/EC Number
53-03-2 (Prednisone); 53-43-0 (Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Suzuki T; Suzuki N; Engleman EG; Mizushima Y; Sakane T
Address
Department of Immunology, St. Marianna University School of Medicine,
Kanagawa, Japan.
Source
Clin Exp Immunol, 1995 Feb, 99:2, 251-5
Abstract
The principal cause of IL-2 deficiency, a common feature of both murine
lupus and human SLE, remains obscure. Recent studies of our own as well
as others have shown that dehydroepiandrosterone (DHEA), an
intermediate compound in testosterone synthesis, significantly
up-regulates IL-2 production of T cells, and that administration of
exogenous DHEA or IL-2 via a vaccinia construct to murine lupus
dramatically reverses their clinical autoimmune diseases. Thus, we have
examined serum levels of DHEA in patients with SLE to test whether
abnormal DHEA activity is associated with IL-2 deficiency of the
patients. We found that nearly all of the patients examined have very
low levels of serum DHEA. The decreased DHEA levels were not simply a
reflection of a long term corticosteroid treatment which may cause
adrenal atrophy, since serum samples drawn at the onset of disease,
which are devoid of corticosteroid treatment, also contained low levels
of DHEA. In addition, exogenous DHEA restored impaired IL-2 production
of T cells from patients with SLE in vitro. These results indicate that
defects of IL-2 synthesis of patients with SLE are at least in part due
to the low DHEA activity in the serum.
Language of Publication
English
Unique Identifier
95153910
----------------------------------------------------------------------------
MeSH Heading (Major)
Interleukin-2|*BI; Lupus Erythematosus, Systemic|*IM;
Prasterone|*BL/*DF; T-Lymphocyte Subsets|*IM
MeSH Heading
Adult; CD4-Positive T-Lymphocytes|IM; CD8-Positive T-Lymphocytes|IM;
Female; Human; Interleukin-4|BI; Interleukin-6|BI; Support, Non-U.S.
Gov't
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE
ISSN
0009-9104
Country of Publication
ENGLAND
CAS Registry/EC Number
0 (Interleukin-2); 0 (Interleukin-4); 0 (Interleukin-6); 53-43-0
(Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Van Vollenhoven RF; McGuire JL
Address
Division of Immunology and Rheumatology, Stanford University Medical
Center, California, USA.
Source
Ann Med Interne (Paris), 1996, 147:4, 290-6
Abstract
Several lines of investigation led to the consideration of
dehydroepiandrosterone (DHEA) as a candidate for hormonal therapy in
systemic lupus erythematosus, including DHEA deficiency in patients
with SLE, the effects of sex steroids on SLE, the immunomodulatory
effects of DHEA, and the results of DHEA in animal models of SLE.
Uncontrolled observations in 50 patients suggested that DHEA has
overall benefits for lupus activity, alleviating specific lupus
symptoms as well the systemic manifestations of lupus, with incremental
benefits over 3 to 12 months of treatment. DHEA, which was very well
tolerated and safe, appeared to decrease the number of lupus flares and
to have a steroid sparing effect. These results were confirmed in a
small placebo-controlled trial, although the results were of borderline
statistical significance. Currently, a number of additional trials with
DHEA are underway, and it is anticipated that DHEA will find its place
as a useful agent in the treatment of SLE.
Language of Publication
English
Unique Identifier
97110599
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*DT; Prasterone|*TU
MeSH Heading
Human
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0003-410X
Country of Publication
FRANCE
CAS Registry/EC Number
53-43-0 (Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Straub RH; Zeuner M; Antoniou E; Schšlmerich J; Lang B
Address
Department of Internal Medicine I, University Hospital, Regensburg,
Germany.
Source
J Rheumatol, 1996 May, 23:5, 856-61
Abstract
OBJECTIVE. To determine whether dehydroepiandrosterone sulfate (DHEAS)
is linked with soluble immune mediators in systemic lupus erythematosus
(SLE). METHODS. DHEAS and various soluble immune mediators were
measured by ELISA in the serum of 35 patients with SLE (26 women, 9
men) and in 41 control subjects. RESULTS. DHEAS was lower in patients
with SLE compared to controls (male 1.29 +/- 0.32 vs 3.04 +/- 0.33
micrograms/ml, p < 0.001; female 0.75 +/- 0.12 vs 2.16 +/- 0.18
micrograms/ml, p < 0.001). The DHEAS reduction was in part dependent on
prior glucocorticosteroid treatment (p < 0.02). After adjustment for
multiple comparisons, there was significant negative correlation
between steroid dose and DHEAS (RRank = -0.426, p = 0.005), but with
none of the soluble immune mediators. No significant difference in the
percentage of steroid treated male and female patients was found (p =
0.220). However, there was positive correlation between DHEAS and
soluble interleukin 2 receptor in women, but not in men, with SLE
[RRank = 0.747 (n = 26, p < 0.0001) vs RRank = -0.1333( n = 9, p =
0.366)] and between DHEAS and soluble intercellular adhesion molecule
in women, but not in men, with SLE [RRank = 0.509 (n = 26, p = 0.005)
vs RRank = 0.4833 (n = 9, p = 0.094)]. CONCLUSION. These data
demonstrate positive interrelation between DHEAS and soluble immune
mediators involved in leukocyte function and leukocyte adhesion only in
female patients with SLE.
Language of Publication
English
Unique Identifier
96315745
----------------------------------------------------------------------------
MeSH Heading (Major)
Cell Adhesion Molecules|*BL/DE; Lupus Erythematosus, Systemic|*BL/DT;
Prasterone|*AA/BL; Receptors, Interleukin-2|*AN/DE
MeSH Heading
Adult; E-Selectin|BL; Female; Glucocorticoids, Synthetic|PD/TU; Human;
Intercellular Adhesion Molecule-1|BL; Interleukins|BL; Male; Middle
Age; Prednisolone|PD/TU; Statistics, Nonparametric; Vascular Cell
Adhesion Molecule-1|BL
----------------------------------------------------------------------------
Publication Type
CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
ISSN
0315-162X
Country of Publication
CANADA
CAS Registry/EC Number
0 (Cell Adhesion Molecules); 0 (E-Selectin); 0 (Glucocorticoids,
Synthetic); 0 (Interleukins); 0 (Receptors, Interleukin-2); 0 (Vascular
Cell Adhesion Molecule-1); 126547-89-5 (Intercellular Adhesion
Molecule-1); 50-24-8 (Prednisolone); 53-43-0 (Prasterone); 651-48-9
(Dehydroepiandrosterone Sulfate)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Hedman M; Nilsson E; de la Torre B
Address
Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Source
Clin Exp Rheumatol, 1989 Nov-Dec, 7:6, 583-8
Abstract
In a clinical study the blood levels of dehydroepiandrosterone sulphate
(DHEAS), pregnenolone sulphate (5-PS), testosterone sulphate (TS) and
their respective unconjugated steroids were measured in: 20 patients
with systemic lupus erythematosus (SLE) who were receiving either no
treatment (11 patients) or else treatment with chloroquine (9
patients), in some cases combined with non-steroidal anti-inflammatory
drugs (NSAIDs); in 26 patients receiving corticosteroid (Prednisolone)
treatment; and in healthy men and women. The patients not on
corticosteroid exhibited substantially reduced DHEAS, 5-PS and TS
levels (geom. mean: 2300 vs. normal 4300 nmol/l DHEAS; 200 vs. 320
nmol/l 5-PS; and 120 vs. 360 nmol/l TS; p less than 0.001),
irrespective of the difference in sex, age or chloroquine treatment.
The patients on corticosteroid treatment displayed a similar pattern of
levels, but the reduction was much more marked than in the patients not
on the steroid (geom. mean: 610 nmol/l DHEAS, 55 nmol/l 5-PS; and 35
nmol/l TS; p less than 0.001). No consistent changes were observed in
the unconjugated steroid levels, although they were also reduced by the
treatment with prednisolone. The data indicate that a deficiency in
sulpho-conjugated steroids is a permanent feature of patients with SLE
and that this is accentuated by the administration of corticosteroid
derivatives. Further studies are needed to establish the
pathophysiological significance of these findings.
Language of Publication
English
Unique Identifier
90125320
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*BL/DT; Prasterone|*AA/BL;
Pregnenolone|*BL; Testosterone|*BL
MeSH Heading
Adolescence; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal|TU;
Diflunisal|TU; Female; Human; Male; Middle Age; Prednisolone|TU;
Support, Non-U.S. Gov't
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE
ISSN
0392-856X
Country of Publication
ITALY
CAS Registry/EC Number
1247-64-9 (pregnenolone sulfate); 145-13-1 (Pregnenolone); 22494-42-4
(Diflunisal); 50-24-8 (Prednisolone); 53-43-0 (Prasterone); 57-85-2
(Testosterone); 651-48-9 (Dehydroepiandrosterone Sulfate)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
FehŽr KG; Bencze G; Ujfalussy J; FehŽr T
Address
National Institute of Rheumatology and Physiotherapy, Budapest,
Hungary.
Source
Acta Med Hung, 1987, 44:4, 321-7
Abstract
Dehydroepiandrosterone (D), D sulphate (DS), testosterone (T) and
oestradiol (OE2) were determined by radioimmunoassay; cortisol (F) by a
spectrofluorimetric method in the serum of 54 female patients with SLE.
The values were evaluated in two age groups (32 patients with active
ovarian function and 22 in menopause). The serum cortisol, T and DS
levels were decreased, and there was no difference in that of free
(unconjugated) D and OE2 concentrations compared to normal female
subjects.
Language of Publication
English
Unique Identifier
88176324
----------------------------------------------------------------------------
MeSH Heading (Major)
Lupus Erythematosus, Systemic|*BL; Sex Hormones|*BL
MeSH Heading
Adolescence; Adult; Comparative Study; Estradiol|BL; Female; Human;
Menopause|BL; Middle Age; Prasterone|AA/BL; Testosterone|BL
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE
ISSN
0236-5286
Country of Publication
HUNGARY
CAS Registry/EC Number
0 (Sex Hormones); 50-28-2 (Estradiol); 53-43-0 (Prasterone); 57-85-2
(Testosterone); 651-48-9 (Dehydroepiandrosterone Sulfate)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Tchernof A; Labrie F; BŽlanger A; DesprŽs JP
Address
Liptd Research Center, Clinical Research Center, Sle foy, Quebec,
Canada.
Source
J Endocrinol, 1996 Sep, 150 Suppl:, S155-64
Abstract
Obesity is a heterogeneous condition and not every obese patient is at
increased risk of cardiovascular diseases (CVD). It is now well
established that the regional distribution of body fat is a critical
correlate of the metabolic complications of obesity. Studies that have
assessed adipose tissue distribution by imaging techniques such as
computed tomography have demonstrated the importance of the
intra-abdominal (visceral) fat depot as a marker of a cluster of
metabolic abnormalities which include glucose intolerance, insulin
resistance, hyper-insulinemia, hypertriglyceridemia, elevated number of
apo B-carrying lipoproteins as well as hypoalphalipoproteinemia.
Although the association between visceral obesity and metabolic
complications can hardly be questioned, it has been suggested that it
may not necessarily represent a causal relationship. For instance,
concomitant alterations in sex steroid levels have been found in both
men and women with abdominal (visceral) obesity which have also been
reported to be significantly correlated with the insulin
resistant-dyslipidemic state found in abdominal obese subjects. In
women, abdominal obesity is associated with increased free testosterone
concentrations and reduced sex hormone binding globulin (SHBG) levels,
whereas in men this condition is associated with reduced testosterone
and adrenal C12 steroid (dehydroepiandrosterone, androstenedione,
androstene-3 beta, 17 beta-diol) levels as well as decreased SHBG
concentrations. These altered steroid and SHBG; levels have been
reported to be independent correlates of the metabolic complications of
visceral obesity although they cannot solely account for the increased
CVD risk found in these patients. In this regard, intervention studies
are clearly warranted to better quantity the respective contribution of
excess visceral adipose tissue and of the concomitant alterations in
sex steroid levels as modulators of metabolic disturbances increasing
CVD risk in obesity.
Language of Publication
English
Unique Identifier
97099222
----------------------------------------------------------------------------
MeSH Heading (Major)
Adipose Tissue|*ME; Cardiovascular Diseases|*ME; Obesity|*ME;
Prasterone|*ME
MeSH Heading
Female; Human; Male; Middle Age; Sex Hormone-Binding Globulin|ME; Sex
Hormones|BL; Support, Non-U.S. Gov't; Viscera
----------------------------------------------------------------------------
Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0022-0795
Country of Publication
ENGLAND
CAS Registry/EC Number
0 (Sex Hormone-Binding Globulin); 0 (Sex Hormones); 53-43-0
(Prasterone)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Title
Author
Nilsson E; de la Torre B; Hedman M; Goobar J; Thšrner A
Address
Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Source
Clin Exp Rheumatol, 1994 Jul-Aug, 12:4, 415-7
Abstract
Blood levels of dehydroepiandrosterone sulphate (DHEAS) were measured
by radioimmunoassay (RIA) in patients with: a) polymyalgia
rheumatica/giant cell arteritis (PMR:TA; N = 25), with and without
cortisone derivative treatment (N = 10 and N = 15, respectively); and
b) primary fibromyalgia (PF; N = 15). The mean DHEAS levels were found
to be significantly reduced in PMR:TA, compared to those in PF (Geom.
mean 820 vs. 2300 nmol/l, respectively; p < 0.001), and the reduction
was more marked in patients on cortisone derivative treatment. The
DHEAS levels found in PF were found to be normal and consistent with
those previously reported in non-immune mediated rheumatological
diseases such as osteoarthritis, and in healthy subjects, using the
same method of analysis. The low levels found in patients with PM:TA
are in accordance with those previously reported in immune-mediated
diseases such as systemic lupus erythematosus (SLE) and rheumatoid
arthritis, suggesting that diminution of DHEAS is a constant
endocrinologic feature in these categories of patients. The
pathophysiological significance of these low DHEAS levels needs to be
investigated.
Language of Publication
English
Unique Identifier
95043630
----------------------------------------------------------------------------
MeSH Heading (Major)
Fibromyalgia|*BL; Polymyalgia Rheumatica|*BL; Prasterone|*AA/BL;
Temporal Arteritis|*BL
MeSH Heading
Adult; Aged; Aged, 80 and over; Female; Human; Male; Middle Age;
Osteoar